# SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

## FORM 12b-25

## NOTIFICATION OF LATE FILING

SEC File Number <u>000-34015</u> Cusip Number: <u>42218Y 10 5</u>

(Check One)	): ☐ Form 10-K and Form 10-K	SB £ Form 20-F	£ Form 11-K	S Form 10-Q and Form 10-QSB	£ Form N-SAR
	For the Period Ended: Set Transition Report Transition Period Period Transition Peri	t on Form 10-K t on Form 20-F on Form 11-K on Form 10-Q on Form N-SAR			
	Read attached i	nstruction sheet be	fore preparing fo	rm. Please print or type.	
Nothing in	this form shall be construed to in	nply that the Comm	nission has verific	ed any information contained her	ein.
If the notifi	cation relates to a portion of the	filing checked abo	ve, identify the ite	em(s) to which the notification re	elates:
Part I - Re	gistrant Information				
3			Health Enhancement Products, Inc.		
	ne if applicable		Western G	lory Hole, Inc.	
Address of	principal executive office (Street	and number)	7740 East Evan	s Road, Suite A101	
City, state a	and zip code		Scottsda	le, AZ 85260	
		_	PART II 2b-25(b) AND (c)	ı	
	ct report could not be filed with ollowing should be completed. (		_	and the registrant seeks relief p	ursuant to Rule 12b-
$\boxtimes$	(a) The reasons described in effort or expense;	reasonable detail	in Part III of this	form could not be eliminated	without unreasonable
X					
	(c) The accountant's stateme	nt or other exhibit	required by Rule	12b-25(c) has been attached if a	oplicable.
					SEC 1344 (11091)

#### Part III - Narrative

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period. (Attach extra sheets if needed.)

The Company is unable to file its Quarterly Report on Form 10-QSB for the quarter ended September 30, 2006 within the prescribed time period because the Company is having difficulty obtaining certain information that is necessary to the completion of the Form 10-QSB. The Company intends to file its Quarterly Report on Form 10-QSB on or before the 5th calendar day following the prescribed due date.

#### Part IV - Other Information

(1) Name and telephone number of person to contact in regard to this notification

Janet Crance 480 385-3800
(Name) (Area Code) (Telephone number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

Yes ⊠ No □

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes ⊠ No □

The Company expects to report a loss for the quarter ended September 30, 2006 of approximately \$530,000, compared with a net loss of approximately \$4.4 million in the comparable prior quarter. The estimated \$3.9 million decrease in net loss for the quarter ended September 30, 2006, compared to the comparable prior quarter, is primarily attributable to a \$1.4 million decrease in stock based compensation to consultants and a \$2.8 million decrease in stock based finance costs, partially offset by an approximate \$250,000 increase in selling, general and administrative expenses.

The Company expects to report a loss for the nine months ended September 30, 2006 of approximately \$2.7 million, compared with a net loss of \$5.1 million in the comparable prior period. The estimated \$2.4 million decrease in net loss for the nine months ended September 30, 2006, compared to the comparable prior period, is primarily attributable to a \$200,000 increase in sales and a \$2.8 million decrease in stock based finance costs, partially offset by a \$120,000 increase in cost of sales (stock based compensation to employees), a \$135,000 increase in expenses related to clinical trials and an approximate \$310,000 increase in selling, general and administrative expense.

Health Enhancement Products, Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 14, 2006 By: /s/ Janet Crance

Name: Janet Crance

Title: Chief Accounting Officer

SEC 1344 (11091)